Dexcom (DXCM) Revenue (2010 - 2026)

Dexcom (DXCM) has reported Revenue for 17 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 13.08% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $5.0 billion, a 15.54% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 15.6% from the prior year.
• Revenue was $1.3 billion for Q2 2026 at Dexcom, up from $1.2 billion in the prior quarter.
• Over five years, Revenue peaked at $1.3 billion in Q2 2026 and troughed at $628.8 million in Q1 2022.
• A 5-year average of $984.9 million and a median of $999.2 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue gained 26.9% in 2023 and grew 1.97% in 2024, its largest moves.
• Over 5 years, Revenue stood at $815.2 million in 2022, then grew by 26.9% to $1.0 billion in 2023, then advanced by 7.64% to $1.1 billion in 2024, then increased by 13.12% to $1.3 billion in 2025, then climbed by 3.87% to $1.3 billion in 2026.
• The last three Revenue figures came in at $1.3 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.